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OBJECTIVES The aim of this study was to evaluate the serum levels of carbohydrate antigen 125 (CA125)
in patients with congestive heart failure (CHF).
BACKGROUND CA125 is a glycoprotein produced by serosal epithelium, found to be increased in ovarian
cancer.
METHODS Serum levels of CA125 were obtained in 286 patients (122 males and 164 females; age 69 
13 years) with CHF (left ventricular ejection fraction 30  11%). A non-invasive evaluation
was obtained by Doppler echocardiography; right heart catheterization was performed in 88
patients. An attempt to adjust medical therapy to maximally tolerated doses was done, and
CA125 was repeated after 18 days (range 7 to 40) in 80 patients. The mean follow-up
duration was 6  3 months in 240 patients.
RESULTS The mean value of CA125 was 68  83 U/ml (range 3 to 537): 71  85 in men and 56 
64 U/ml in women (p  NS). CA125 above the normal value (35 U/ml) was found in 152
(53%) of 286 patients; it was higher in patients with advanced New York Heart Association
(NYHA) functional class (n  140 in class I/II: 15  9 U/ml; n  63 in class III: 57  18
U/ml; n 83 in class IV: 167 94 U/ml; p 0.005). CA125 was related to the deceleration
time of early filling on transmitral Doppler (r  0.63, p  0.05) and to pulmonary artery
wedge pressure (r  0.66, p  0.05) and right atrial pressure (r  0.69, p  0.05). During
6  3 months of follow-up, a combined end point of mortality and CHF hospitalization was
observed in 16 of 127 patients with CA125 35 U/ml, compared with 70 of 113 patients
with CA125 35 U/ml (p  0.01). After medical treatment optimization, NYHA class
decreased by more than one grade in 56 of 80 patients and was unchanged or increased in 24
patients: CA125 decreased from 125  98 to 53  61 U/ml (p  0.001) in the former and
changed from 130  81 to 153  61 U/ml (p  NS) in the latter.
CONCLUSIONS Our data suggest that CA125 is related to CHF severity and short-term prognosis.
Furthermore, fluctuations of CA125 serum levels over time may reflect changes induced by
therapy. Therefore, measurements of CA 125 serum levels might be proposed for the serial
assessment of CHF patients. (J Am Coll Cardiol 2003;41:1805–11) © 2003 by the
American College of Cardiology Foundation
The search for new prognostic markers in congestive heart
failure (CHF) has intensified recently, along with interest in
the use of surrogate end points, risk stratification, and
clinical decision-making in these patients (1). Accordingly,
several parameters have a demonstrated prognostic value in
CHF patients over time: indexes of left and right ventricular
function, exercise tolerance, autonomic nervous system
markers, and biologic markers. Among the biologic mark-
ers, not only the neurohormones, such as plasma norepi-
nephrine and atrial natriuretic peptides (particularly brain
natriuretic peptide [BNP]), but also markers of inflamma-
tion and cytokines, such as tumor necrosis factor and
interleukin-6, have shown a relationship with outcome in
CHF patients (2–7).
An increase in the blood levels of carbohydrate antigen
125 (CA125), a tumoral marker initially related to ovarian
cancer (8,9), has been recently reported in a group of CHF
patients evaluated for heart transplantation and was shown
to be related to the severity of symptoms (10). The aim of
the present study was to measure the blood levels of CA125
in a large group of patients with symptomatic left ventricular
dysfunction and to determine the potential relationship
between this tumoral marker and the severity of CHF, the
extent of underlying cardiac abnormalities, and short-term
outcome.
METHODS
Study population. We prospectively evaluated 286 patients
consecutively admitted with CHF to the Department of
Cardiology, Spedali Civili and University of Brescia, Italy,
in a period of 18 months. The diagnosis of CHF was based
on clinical presentation and standard investigations; further-
more, all patients had at least one hospital admission for
From the *Cattedra di Cardiologia, Universita` di Brescia; †Unita` Operativa di
Policardiografia; ‡III Laboratorio di Analisi, Spedali Civili, Brescia, Italy; and
§Cardiology Division, University of Worcester, Worcester, Massachusetts.
Manuscript received November 4, 2002; revised manuscript received January 18,
2003, accepted February 6, 2003.
Journal of the American College of Cardiology Vol. 41, No. 10, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00311-5
CHF before inclusion in the study. We excluded patients
with a recent acute coronary syndrome (3 months), those
awaiting coronary artery bypass graft or valvular surgery, and
those with any evidence of active infection, cancer, end-
stage liver disease, or renal failure. The clinical characteris-
tics of the study population are listed in Table 1.
Echocardiographic Examination and CA125 Measure-
ment. All patients underwent a clinical examination, a
two-dimensional Doppler echocardiographic examination,
and venous blood sampling for CA125 analysis (see next
paragraph) on the day of admission. Two-dimensional
echocardiography was performed with commercially avail-
able equipment. Measured variables included left ventricular
end-diastolic (LVEDD) and end-systolic diameter, using
two-dimensionally guided M-mode echocardiography. The
left ventricular ejection fraction (LVEF) was calculated
using the Simpson method from the apical four-chamber
view. The severity of mitral and tricuspid regurgitation was
evaluated by means of color Doppler flow imaging and
semiquantitatively expressed using a scale from 0 to 4
(11). On the pulsed Doppler tracing of transmitral blood
flow, recorded at the tips of the mitral leaflets from the
apical four-chamber view, the following parameters were
measured: peak velocity in early filling (E) and during atrial
systole (A), expressed in cm/s, and their ratio (E/A), and the
deceleration time of early filling (DT), expressed in ms.
These parameters, particularly DT, have been shown to
significantly correlate with invasively measured left atrial
pressure (12).
Serum levels of CA125 were determined using a com-
mercially available kit (Tumor Markers CA125 AxSYM
System, Abbott Laboratories, Abbott Park, Illinois). The
AxSYM CA125 assay is based on microparticle enzyme
immunoassay; this technology uses a solution of suspended,
submicron-sized latex particles to measure analytes. CA125
assay values are defined by using the OC125 monoclonal
antibody. The OC125 monoclonal antibody is reactive with
repeating OC125-reactive determinants, expressed by a
high percentage of non-mucinous ovarian carcinomas (se-
rous, endometrioid, clear cell, and undifferentiated histolo-
gies) and epithelial ovarian carcinoma cell lines. OC125-
reactive determinants are not produced by normal cell lines
and have not been found in normal or benign ovarian tissues
of either fetuses or adults. However, OC125-reactive deter-
minants have been reported to be detected in the pleura,
pericardium, and peritoneum of adults. The upper normal
limit of CA125 is 35 U/ml (8,13). The analytical sensitivity
of the AxSyM CA125 was calculated to be 2 U/ml; the
median intra-assay and inter-assay coefficients of variation
are 5% and 7.5%, respectively (13).
A right heart catheterization (RHC) using a Swan-Ganz
catheter was performed in 88 CHF patients within 24 to
48 h of CA125 measurement and in the absence of relevant
changes in the clinical picture. Standard parameters were
obtained, such as pressures in right heart chambers, pulmo-
nary artery wedge pressure (PAWP), and cardiac output (in
triplicate), using the thermodilution method.
Echocardiographic and CA125 measurements were re-
peated (mean interval 18 days [range 7 to 40]) in 80 patients
with moderate-to-severe CHF (New York Heart Associa-
tion [NYHA] functional class III and IV) after an attempt
to optimize medical treatment, usually by increasing the
dosage of furosemide and adding metolazone when neces-
sary, to reduce pulmonary and systemic congestion, and by
gradually increasing the daily dosage of angiotensin-
converting enzyme inhibitors to maximally tolerated doses,
according to the evidence derived from randomized trials.
Furthermore, in some patients, oral or transdermal nitrates
were added as needed.
Follow-up. Complete follow-up data were available in 240
patients with a follow-up of at least three months from the
time of study inclusion. The mean follow-up duration was
6  3 months (range 3 to 12). Clinical end points included
total mortality, cardiovascular mortality (sudden and non-
sudden death), and hospitalization for any cardiovascular
cause. A combined end point, including total mortality and
hospital admission for CHF, was also considered. The
clinician doing the follow-up evaluation was blinded to the
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CA125  carbohydrate antigen 125
CHF  congestive heart failure
DT  deceleration time of early filling
LVEDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
PAWP  pulmonary artery wedge pressure
RAP  right atrial pressure
RHC  right heart catheterization
Table 1. Clinical Characteristics of CHF Patients (n  286)
Age (yrs) 69  13
Men/women 122/164
Body mass index (kg/m2) 25  9.3
NYHA functional class
Mean
I (%) 10 (3.5%)
II (%) 130 (45.5%)
III (%) 63 (22%)
IV (%) 83 (29%)
LVEF (%) 30  11
Etiology (%)
Coronary artery disease 60
Dilated cardiomyopathy 23
Hypertensive heart disease 11
Other 6
Medication use (%)
ACE inhibitor 95
Diuretic 88
Digitalis 60
Beta-blocker 50
Data are presented as the mean value  SD or number (%) or percentage of patients.
ACE  angiotensin-converting enzyme; LVEF  left ventricular ejection
fraction; NYHA  New York Heart Association.
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CA125 results. The study was approved by the local ethics
committee, and all patients gave written, informed consent.
Statistical analysis. Data are presented as the mean
value  SD. Logarithmic transformation was used for some
variables (CA125, DT) to reduce skewness and kurtosis
values toward a normal distribution. Differences between
the study groups were assessed by using the Student t test
and one-way or two-way analysis of variance for repeated
measures with post hoc Scheffe´ correction. A p value 0.05
was considered statistically significant. Multiple correlation
analysis with stepwise forward and backward methods was
used to assess the factors related to CA125 levels, and final
regression analysis shows only the variables confirmed by
both methods. Survival curves were generated by the
Kaplan-Meier method, and the log-rank test was used to
evaluate the significance of differences between groups.
RESULTS
The mean serum level of CA125 in the whole population
was 68  83 U/ml (range 3 to 537): 71  85 U/ml in men
and 56  64 U/ml in women (p  NS by the t test). Serum
levels of CA125 over the normal range (35 U/ml) were
found in 152 (53%) of 286 CHF patients; CA125 values
35 U/ml were observed in none of 10 patients in NYHA
class I, in 16 (12%) of 130 patients in class II, in 53 (84%)
of 63 patients in class III, and in all 83 (100%) patients in
class IV. Patients in class I/II were similar in terms of
demographic characteristics, etiology of CHF, LVEF, and
medication use. Accordingly, they were considered together
in the subsequent analysis. Mean values of CA125 were
significantly higher (p  0.001) in patients in class III/IV
than in those in class I/II (Table 2, Fig. 1).
Multiple regression analysis showed that the following
variables were predictive of CA125 values: LVEDD, DT,
PAWP, and right atrial pressure (RAP) (final R  0.78,
p  0.005). After the results of multiple regression analysis,
we evaluated simple correlations between CA125 and sev-
eral Doppler echocardiographic and hemodynamic variables
(the latter limited to 88 patients in whom RHC was
performed), which are listed in Table 3. An inverse relation
(statistically significant) was found between CA125 levels
and DT, a reliable non-invasive index of left atrial pressure.
This result was confirmed by the similar r value found
between CA125 and PAWP obtained during RHC in the
subgroup of 88 CHF patients. Furthermore, CA125 levels
were also significantly related to the invasively determined
RAP. There was no significant correlation between CA125
and LVEF or LVEDD.
Among those patients in whom an attempt to optimize
medical treatment was performed and CA125 measurement
repeated after a mean interval of 18 days, a clinical improve-
ment, as expressed by a decrease in NYHA functional class
of one grade or more, was observed in 56 of 80 patients,
whereas no change or even a clinical worsening was ob-
served in the remaining 24 patients. The changes observed
after treatment in the relevant Doppler echocardiographic
and hemodynamic variables and CA125 levels in both
groups are listed in Table 4. Of interest, the serum level of
CA125 decreased from 125  98 to 53  61 U/ml (p 
0.05) in patients showing a clinical improvement, whereas it
changed from 130  81 to 153  61 U/ml (p  NS) in
those patients with no change or even a worsening in their
clinical picture (Fig. 2). Twenty of 56 patients showing a
clinical improvement after therapy had a normalization
(35 U/ml) of a previously elevated CA125 level, compared
with none of 24 patients without clinical improvement (p
0.05). The behavior of CA125 in the two groups paralleled
that of DT and PAWP (hemodynamic data are available in
35 patients), as reported in Table 4.
Among 240 patients followed for a mean period of 6  3
months, 39 died and 47 were readmitted to the hospital at
least once for worsening CHF. The cause of death was
cardiovascular in all patients. The combined end point (total
mortality and hospitalization for worsening CHF) was
Table 2. Clinical, Doppler Echocardiographic and Hemodynamic Parameters, and CA125 Serum Levels in CHF Patients Classified
According to NYHA Functional Class
NYHA Class I to II
(n  140)
NYHA Class III
(n  63)
NYHA Class IV
(n  83)
p Value
(global)
Men/women 42/98 31/32 49/34
Body mass index (kg/m2) 26  12 26  12 26  12 NS
Serum creatinine (mg%) 1.35  0.67 1.5  0.8 1.43  0.66 NS
CA125 (U/ml) 15  9 57  18* 167  94†‡  0.005
LVEF (%) 32  12 29  11 27  9‡  0.005
Mitral regurgitation score 2  0.8 2.7  0.8* 2.9  0.7‡  0.005
Tricuspid regurgitation score 1.3  0.8 2.25  0.8* 2.6  0.8‡§  0.005
E/A ratio 1.26  0.5 1.9  0.9* 2.3  0.5†‡  0.005
DT (ms) 169  45 131  28* 107  27†‡  0.005
RAP (mm Hg) 7  3 13  4* 16  5†‡¶  0.005
PASP (mm Hg) 35  10 51  11* 55  11‡¶  0.005
PAWP (mm Hg) 13.5  5 21  5* 25  6‡¶  0.005
Analysis of variance with posthoc Scheffe´ correction (simple effect): *p  0.005 between NYHA class I to II and III. †p  0.005 between NYHA class III and IV. ‡p  0.005
between NYHA class I to II and IV. §p  0.01 between NYHA class III and IV. ¶p  0.05 between NYHA class III and IV. Differences not indicated were not significant.
Data are presented as the mean value  SD.
CA125  carbohydrate antigen 125; DT  deceleration time; E/A  ratio of early transmitral to atrial flow velocity; LVEF  left ventricular ejection fraction; PASP 
pulmonary artery systolic pressure; NYHA  New York Heart Association; PAWP  pulmonary artery wedge pressure; RAP  right atrial pressure.
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observed in 70 of 113 patients with baseline CA125 values
35 U/ml, compared with 16 of 127 patients with baseline
CA125 values 35 U/ml (p  0.01 by the log-rank test).
Kaplan-Meier cumulative survival curves separated accord-
ing to CA125 levels are presented in Figure 3.
In patients with persistently high values of CA125 (on at
least two separate occasions), a diagnostic work-up for
cancer was negative. Furthermore, non-malignant diseases
potentially responsible for CA125 elevations, such as end-
stage renal failure and liver cirrhosis, were also excluded. A
pleural effusion was detected on the chest X-ray film in
seven patients; mild pericardial effusion on the echocardio-
gram was observed in two patients; and ascites was found in
one patient; all of these patients were in NYHA class IV and
showed an increase of CA125 levels above normal values.
Pleural effusion disappeared after aggressive medical therapy
of CHF, and a concomitant reduction of CA125 was found
in four patients in whom this measurement was repeated.
The patient with ascites underwent paracentesis, and the
peritoneal fluid was negative for neoplastic cells. The patient
died 12 days later due to refractory heart failure.
DISCUSSION
The principal results of this study of patients with CHF is
that serum levels of CA125 correlated with clinical status, as
demonstrated by significantly higher values in NYHA class
III/IV, compared with those in class I/II. Moreover, CA125
levels also correlated with invasive and non-invasive hemo-
dynamic abnormalities, particularly the level of RAP and
PAWP. In patients with moderate-to-severe CHF, abnor-
mally elevated values of CA125 were significantly reduced
by aggressive medical treatment, in parallel with improve-
ments of the clinical picture and indexes of hemodynamic
impairment. Finally, elevated serum levels of CA125 were
predictive of a worse prognosis in short-term follow-up.
An increase of serum levels of CA125 has been initially
described in women affected by ovarian carcinoma, espe-
cially with peritoneum involvement (8,9). Accordingly,
serial measurements of this tumoral marker are currently
used in the follow-up of these patients and to evaluate the
response to therapy (14). High CA125 values have also been
observed in patients with lung, breast, uterine, or gastroin-
testinal tract cancer (15). Furthermore, it has been reported
that some non-malignant diseases such as nephrotic syn-
drome and hepatic cirrhosis, along with their concomitant
serosal effusions (i.e., fluid accumulation in the pleural,
peritoneal, or pericardial space), may be associated with
Figure 1. Serum levels of carbohydrate antigen 125 (CA125) in congestive heart failure patients classified according to the different New York Heart
Association (NYHA) functional classes. Data are expressed as the mean value  SD. Difference between groups were assessed using analysis of variance
with post hoc Scheffe´ correction. See text for details.
Table 3. Multiple Regression Analysis and Simple Correlation
Between CA125 and Serum Sodium and Doppler
Echocardiographic and Hemodynamic Parameters
r p Value
Multiple regression analysis (R) 0.78 0.005
LVEF* 0.15 NS
LVEDD* 0.11 NS
DT* 0.63 0.05
E/A ratio 0.60 0.05
RAP* 0.69 0.05
PASP 0.58 0.05
PAWP* 0.66 0.05
Serum sodium 0.18 NS
*Variables entered in multiple regression analysis forward and backward. See text for
details. All values, except for multiple regression analysis, are expressed as r.
LVEDD  left ventricular end-diastolic diameter; other abbreviations as in
Table 2.
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elevated serum levels of CA125, and even higher CA125
values in the serosal fluids. In contrast, CA125 levels were
normal in those patients without serosal effusions (16,17).
Subsequent studies have demonstrated that mesothelial cells
from the pleura and peritoneum are able to produce CA125
(18). Of interest, blood levels of CA125 above normal were
also found in 65% of 57 patients with pericardial effusion of
different etiologies, including 25 with some degree of heart
failure; significantly higher values of CA125 were found in
subjects with a larger effusion, as documented by echocar-
diography, and were reported to decrease or even normalize
along with a reduction or disappearance of effusion (19).
Furthermore, in 17 patients, the pericardial tissue obtained
at autopsy was stained with anti-CA125 antibodies: serum
and pericardium CA125 levels were significantly higher in
subjects with CA125-positive-stained pericardium, com-
pared with those in whom the pericardium was negative for
CA125, confirming a pericardial production of this marker
(19). Thus, in chronic non-malignant diseases, high plasma
levels of CA125 have been attributed to its production by
serosal mesothelium, as a consequence of inflammation,
stasis, or other stimulatory mechanisms.
Nagele et al. (10) measured CA125 serum levels in CHF
patients evaluated for heart transplantation; although the
prevalence of pleural or pericardial effusion was not re-
ported, the authors found an increase in CA125 levels above
normal not only in patients with advanced CHF (NYHA
class III/IV), in whom some degree of fluid accumulation
may be expected, but also in those with mild or no
symptoms (NYHA I/II), in whom serosal effusion is un-
likely. In our study population, CA125 was elevated both in
the few patients with pleural, pericardial, or peritoneal
Table 4. Characteristics of 80 Patients Before and After Medical Therapy Optimization, Classified According to Clinical
Improvement or No Change/Worsening
NYHA Class Reduced (n  56) NYHA Class Unchanged or Increased (n  24)
Before MTO After MTO p Value Before MTO After MTO p Value
NYHA class* 3  0.8 1.5  0.5 0.005 3.6  0.5 3.5  0.5 NS
LVEF (%)* 28  10 32  11 NS 25.5  8.5 25.5  8.4 NS
E/A ratio* 1.8  0.5 1.3  0.5 0.001 2.4  0.6 2.3  0.7 NS
DT (ms)* 123  32 167  47 0.001 109  20 111  23 NS
PAWP (mm Hg)*† 23  6 13  3 0.001 23  5 24  6 NS
CA125 (U/ml) 125  98 53  61 0.001 130  81 153  61 NS
*Analysis of variance interaction has been verified for all comparisons: all parameters obtained before optimization were similar between the two groups, whereas differences
between groups observed after optimization were statistically significant (p  0.001 for all variables). †Data available for 35 patients. Data are presented as the mean value 
SD.
MTO  medical therapy optimization; other abbreviations as in Table 2.
Figure 2. Changes in serum levels of carbohydrate antigen 125 (CA125) after optimization of medical therapy for congestive heart failure. The left panel
presents data from the patients in whom a clinical improvement after therapy was observed. The right panel presents data from the patients in whom no
clinical improvement, or even a worsening, was observed despite intensive medical treatment. See text for details.
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effusion and in the large majority of patients with moderate-
to-severe CHF and no effusion. It could be hypothesized
that CA125 might be produced from mesothelial cells, even
in the absence of classic stimuli (such as fluid accumulation),
and/or that it might also be secreted by other cell lines. Of
interest, it has been reported that CA125 is produced and
released from ovarian cancer cells and lymphoma cells when
stimulated by cytokines (20–22), such as tumor necrosis
factor and interleukin-6, which are also elevated in heart
failure (4–7). However, the potential pathogenetic link
between cytokine activation and production of CA125 in
CHF patients, as well as its clinical relevance, needs further
study.
To our knowledge, there is only one published study that
has evaluated the behavior of CA125 in patients with
chronic CHF (10). In contrast to our results, Nagele et al.
(10) found that mean values of CA125 serum levels were
higher than normal not only in patients with moderate-to-
severe CHF (NYHA class III/IV) but also in patients with
mild symptoms (class II) and even in those with asymptom-
atic left ventricular dysfunction (class I). Furthermore, they
reported higher mean values of CA125 in each functional
class than those we observed in our study population; this
may reflect both the different analytical method used for
measuring CA125 levels, compared with that used in our
study, and, possibly, differences in the study populations, as
all individuals were evaluated for heart transplantation (10).
Consistent with our findings was a significant correlation
between CA125 and filling pressures, as well as a reduction
of CA125 serum levels in a subgroup of patients after
improvement in clinical status. No data on the prognostic
role of CA125 were reported in the study (10).
Study limitations. Several points regarding the meaning of
CA125 elevations in CHF patients still need to be ad-
dressed, such as its regulatory mechanisms and sites of
production. Little is known about the biologic role of this
substance: whether it simply reflects the increased activation
of the cytokine pathway (or other pathophysiologic path-
ways), or whether CA125 is an active substance truly
responsible for myocardial and/or peripheral dysfunction.
The relationship between CA125 and indexes of functional
capacity that are more objective than NYHA classification,
such as exercise tolerance and long-term outcome, should be
investigated. In many regards, CA125 at this early stage
appears to resemble some aspects of BNP. Preliminary data
show a good correlation between simultaneous CA125 and
BNP levels in 54 CHF patients (r  0.74, p  0.05)
(unpublished observation). Further work will need to clarify
the relative value of CA125 compared with BNP in the
diagnosis and subsequent treatment of CHF.
Nevertheless, based on the results reported herein, the
serum level of CA125 seems to represent an easily obtain-
Figure 3. Kaplan-Meier curves for congestive heart failure patients classified according to baseline serum levels of carbohydrate antigen 125 (CA125). See
text for details. Cumulative proportion surviving: open circles  complete; solid plus signs  censored.
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able and repeatable, relatively inexpensive (less than $4 per
patient in Italy), and reliable marker of moderate-to-severe
CHF, which appears to be related to hemodynamic abnor-
malities and might reflect both the effects of treatment and
short-term prognosis. Similar to more sophisticated hor-
monal and immunologic markers, it might therefore be
proposed for the serial assessment of patients with CHF.
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